David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

They cost so much partly because of the time and money it took to develop them, Eli Lilly's CEO said. Drugmakers want to capture a fair share of the value they create before patents expire ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to ...

Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice Eli Lilly is betting big ... Trump will meet on Thursday with chief executives from major drugmakers, a White ...

Philips CEO sees subdued China sales this year The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly's blockbuster weight loss and diabetes drugs ...